BA
ADMA icon

Bridgewater Associates’s ADMA Biologics ADMA Stock Holding History

Bridgewater Associates’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.36M Sell
401,059
-71,049
-15% -$648K 0.01% 570
2026
Q1 		$4.25M Buy
472,108
+285,637
+153% +$4.51M 0.02% 458
2025
Q4 		$3.4M Buy
186,471
+126,189
+209% +$2.13M 0.01% 636
2025
Q3 		$884K Buy
+60,282
New +$1.03M ﹤0.01% 863

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bridgewater Associates's ADMA Position: Q2 2026 in Review

Bridgewater Associates reduced its ADMA Biologics (ADMA) stake by 15% in Q2 2026, selling an estimated $648K and leaving 401,059 shares worth $3.36M. The position accounts for 0.01% of the portfolio, ranked #570.

Bridgewater Associates first reported a position in ADMA in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.25M in Q1 2026. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Bridgewater Associates held 401,059 shares of ADMA Biologics worth $3.36M as of Q2 2026.
  • Bridgewater Associates sold 71,049 ADMA Biologics shares in Q2 2026, an estimated $648K.
  • ADMA Biologics made up 0.01% of Bridgewater Associates's portfolio in Q2 2026, its #570 holding.
  • Bridgewater Associates first reported a position in ADMA Biologics in Q3 2025 and has held it in 4 quarters since.
  • Bridgewater Associates's ADMA Biologics position peaked at $4.25M in Q1 2026.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.